

Niamh Buckley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2072705/publications.pdf>

Version: 2024-02-01

38
papers

1,218
citations

471371

17
h-index

414303

32
g-index

39
all docs

39
docs citations

39
times ranked

2642
citing authors

#	ARTICLE	IF	CITATIONS
1	Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw199.	3.0	338
2	BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers. <i>Oncogene</i> , 2012, 31, 3667-3678.	2.6	77
3	BRCA1 transcriptionally regulates genes associated with the basal-like phenotype in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 721-731.	1.1	68
4	T-box 2 represses NDRG1 through an EGR1-dependent mechanism to drive the proliferation of breast cancer cells. <i>Oncogene</i> , 2010, 29, 3252-3262.	2.6	57
5	The 2,5 oligoadenylate synthetase/RNaseL pathway is a novel effector of BRCA1- and interferon- β -mediated apoptosis. <i>Oncogene</i> , 2005, 24, 5492-5501.	2.6	53
6	BRCA1 Regulates IFN- β Signaling through a Mechanism Involving the Type I IFNs. <i>Molecular Cancer Research</i> , 2007, 5, 261-270.	1.5	44
7	BRCA1 is a key regulator of breast differentiation through activation of Notch signalling with implications for anti-endocrine treatment of breast cancers. <i>Nucleic Acids Research</i> , 2013, 41, 8601-8614.	6.5	44
8	Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer. <i>Journal of Oncology</i> , 2018, 2018, 1-14.	0.6	44
9	Dual Mechanisms of LYN Kinase Dysregulation Drive Aggressive Behavior in Breast Cancer Cells. <i>Cell Reports</i> , 2018, 25, 3674-3692.e10.	2.9	43
10	Rational design and characterisation of a linear cell penetrating peptide for non-viral gene delivery. <i>Journal of Controlled Release</i> , 2021, 330, 1288-1299.	4.8	40
11	Quantification of HER2 heterogeneity in breast cancer—implications for identification of sub-dominant clones for personalised treatment. <i>Scientific Reports</i> , 2016, 6, 23383.	1.6	38
12	TBX2 interacts with heterochromatin protein 1 to recruit a novel repression complex to EGR1-targeted promoters to drive the proliferation of breast cancer cells. <i>Oncogene</i> , 2019, 38, 5971-5986.	2.6	38
13	TBX2 represses CST6 resulting in uncontrolled legumain activity to sustain breast cancer proliferation: a novel cancer-selective target pathway with therapeutic opportunities.. <i>Oncotarget</i> , 2014, 5, 1609-1620.	0.8	37
14	The β -Np63 Proteins Are Key Allies of BRCA1 in the Prevention of Basal-Like Breast Cancer. <i>Cancer Research</i> , 2011, 71, 1933-1944.	0.4	35
15	A BRCA1 deficient, NF- κ B driven immune signal predicts good outcome in triple negative breast cancer. <i>Oncotarget</i> , 2016, 7, 19884-19896.	0.8	30
16	BRCA1 — Conductor of the Breast Stem Cell Orchestra: The Role of BRCA1 in Mammary Gland Development and Identification of Cell of Origin of BRCA1 Mutant Breast Cancer. <i>Stem Cell Reviews and Reports</i> , 2012, 8, 982-993.	5.6	29
17	S100A2 is a BRCA1/p63 coregulated tumour suppressor gene with roles in the regulation of mutant p53 stability. <i>Cell Death and Disease</i> , 2014, 5, e1070-e1070.	2.7	24
18	The clinical and molecular significance associated with STING signaling in breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 81.	2.3	21

#	ARTICLE	IF	CITATIONS
19	Thromboxane A2 receptor (TBXA2R) is a potent survival factor for triple negative breast cancers (TNBCs). <i>Oncotarget</i> , 2016, 7, 55458-55472.	0.8	19
20	Defining the molecular evolution of extrauterine high grade serous carcinoma. <i>Gynecologic Oncology</i> , 2019, 155, 305-317.	0.6	17
21	A Novel Role for Cathepsin S as a Potential Biomarker in Triple Negative Breast Cancer. <i>Journal of Oncology</i> , 2019, 2019, 1-12.	0.6	16
22	Exploring the Potential of MicroRNA Let-7c as a Therapeutic for Prostate Cancer. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 18, 927-937.	2.3	16
23	PDLIM2 Is a Marker of Adhesion and β -Catenin Activity in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2019, 79, 2619-2633.	0.4	14
24	Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer. <i>British Journal of Cancer</i> , 2022, 126, 247-258.	2.9	14
25	Osteopontin can act as an effector for a germline mutation of BRCA1 in malignant transformation of breast cancer-related cells. <i>Cancer Science</i> , 2010, 101, 1354-1360.	1.7	12
26	NUP98 is a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer. <i>BMC Cancer</i> , 2019, 19, 236.	1.1	11
27	Molecular classification of non-invasive breast lesions for personalised therapy and chemoprevention. <i>Oncotarget</i> , 2015, 6, 43244-43254.	0.8	8
28	Investigating Radiotherapy Response in a Novel Syngeneic Model of Prostate Cancer. <i>Cancers</i> , 2020, 12, 2804.	1.7	8
29	Glucocorticoid Receptor Expression Predicts Good Outcome in response to Taxane-Free, Anthracycline-Based Therapy in Triple Negative Breast Cancer. <i>Journal of Oncology</i> , 2020, 2020, 1-10.	0.6	7
30	Pin1 plays a key role in the response to treatment and clinical outcome in triple negative breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592090604.	1.4	5
31	Exploiting the anticancer effects of a nitrogen bisphosphonate nanomedicine for glioblastoma multiforme. <i>Journal of Nanobiotechnology</i> , 2021, 19, 127.	4.2	5
32	Trastuzumab cardiotoxicity in HER2-positive breast cancer patients in tertiary health care center, sultanate of Oman. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 312-321.	0.5	4
33	Abstract 4000: A DNA damage response deficiency (DDR) group in breast cancer is associated with activation of the STING innate immune pathway and PD-L1 expression. , 2016, , .		1
34	Abstract C105: DNA damage response deficiency (DDR) in breast cancer is associated with a STING-dependent innate immune response. , 2015, , .		1
35	Novel prognostic biomarkers in high grade serous carcinoma of the pelvis: review of current markers and an introduction to the potassium channel gene KCNK1 as a new biomarker. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2016, 206, e28.	0.5	0
36	Abstract B051: The identification of the Thromboxane A2 receptor as an oncogenic driver in triple-negative breast cancer. , 2013, , .		0

#	ARTICLE	IF	CITATIONS
37	Abstract 2270: A BRCA1 deficient, NF κ B driven immune signal predicts good outcome in triple negative breast cancer. , 2016, , .		0
38	Abstract 347: The role of Pin1 in chemosensitivity of BRCA1-deficient breast cancers. , 2017, , .		0